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Aim. To assess the safety of photodynamic therapy (PDT) using talaporfin sodium on the pancreas and surrounding organs in
normal hamsters.Methods. Fluorescencemicroscopy documented talaporfin levels in liver, duodenum, and pancreas up to 24 hours
after photosensitisation. Lesion size in liver 3 days after PDT (50 J, 5mg/kg, variable drug-light interval (DLI)) was documented
to optimise the DLI. Using optimum DLI, pancreas and surrounding organs were treated with laser fibre touching the surface and
animals were killed at 3 or 21 days. Results. Peak fluorescence was seen in duodenum and pancreas at 15mins (second lower peak
at 2 hours). Liver fluorescence was consistently high (peak 1 hour) until after 4 hours. Optimum DLI was seen at 15 minutes. The
pancreas was relatively resistant to direct PDT injury (small lesions at high doses) but surrounding stomach, duodenum, and liver
were more susceptible with evidence of adhesions and full thickness damage (localised peritonitis and duodenal perforation at
highest doses). Conclusion. The safety profile is similar to PDT with longer acting photosensitisers. The pancreas appears safe to
treat, but care is required to avoid high light doses to the intestinal tract, particularly the duodenum.
1. Introduction
In the UK approximately 8000 people are diagnosed with
pancreatic adenocarcinoma each year [1, 2]. Surgical resec-
tion is the only chance of cure and is only possible in a
minority of subjects. Even after resection, themedian survival
is only 10–20 months and only 12–35% of resected patients
survive five years or more [3–6]. Palliative chemotherapy can
improve both quality of life and survival in advanced disease
[7–10], but overall, the long-term prognosis of the disease is
poor with a one-year survival rate of 15–39% [11–16]. These
dismal results stimulated the search for a minimally invasive
treatment capable of local destruction of tumour tissue with
low morbidity that might have a place in the treatment of
unresectable disease.
Photodynamic therapy (PDT) for pancreatic cancer was
first described in 2002 [17]. This showed that image guided,
interstitial PDT using the photosensitiser mTHPC (Foscan)
could produce localised tumour necrosis with lowmorbidity,
although the prolonged skin photosensitivity associated with
mTHPC limited its acceptability for patients. This stimulated
the search for shorter acting photosensitisers, with less
potential photosensitivity.
Talaporfin sodium (LS11, Laserphyrin, mono-L-aspartyl
chlorin; Light Sciences Corporation, Snoqualmie, WA, USA)
is a chlorophyll and L-aspartic acid derived, pure photo-
sensitiser codeveloped by Meiji Seika and Nippon Petro-
chemicals. The expected 1-2 week cutaneous photosensitivity
following talaporfin administration is considerably shorter
than that associated with other commonly used agents like
porfimer sodium and mTHPC [18, 19]. In 2004, talaporfin
was approved in Japan for PDT for early stage non-small-
cell lung cancer [20]. The drug is mainly confined to the
vasculature during the first hour after intravenous injection
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and Phase II clinical trials using talaporfin sodium for
palliation of colorectal liver metastases have been completed
with minimal toxicity using drug light intervals of 15–60
minutes [18, 21].
Animal studies have established the safety and potential
efficacy of PDT for pancreatic cancer using a variety of pho-
tosensitisers including mTHPC, dihaematoporphyrin ether
(DHE), and 5-ALA [22–24]. However, the effects and safety
of talaporfin PDT on the normal pancreas and surrounding
abdominal organs have not been studied. This study reports
safety data using the normal female Syrian golden hamster.
2. Methods
The study was undertaken on normal mature, female Syrian
golden hamsters, 90–120 g in weight. Approval was obtained
from the local ethics committee and performed under UK
Home Office licenses issued under “The Protection for
Animals (Scientific Procedures) Act, 1986”. All animals were
cared for within university animal facilities and published
guidelines on the care and treatment of laboratory animals
were followed. All procedures were carried out under general
anaesthesia, initiated by an intraperitoneal injection of Hyp-
norm (fentanyl and fluanisone, Janssen Pharmaceuticals),
midazolam 5mg/mL (Roche Pharmaceuticals), and sterile
water in a 1 : 1 : 2 mixture; and maintained by inhalational
halothane (ICI Pharmaceuticals, Cheshire, UK) with oxygen
supplementation for a maximum duration of two hours.
Subcutaneous buprenorphine hydrochloride (Reckitt & Col-
man Products Ltd., UK) was administered to provide up to
24 hours of postoperative analgesia. No hamster required
further doses of analgesia in the postoperative period.
Talaporfin sodium was kindly supplied free of charge
(Light Sciences Corporation, Snoqualmie, WA, USA) as a
green lyophilised powder in 100mg vials and reconstituted
using sterile normal saline to a suitable concentration for
hamster use. For drug administration, a laparotomy was
performed under sterile conditions to provide access for
direct intracaval injection and light delivery. The animals
remained in a darkened environment for a total of 48 hours
after photosensitisation and were assessed daily.
2.1. Fluorescence Microscopy. The pharmacokinetics of tala-
porfinwere studied using fluorescencemicroscopy. Hamsters
were injected with 5mg/kg and killed at time intervals of 15,
30, 60, 120, and 240minutes and 24hours after sensitisation (2
animals at each time point, including 2 unsensitised animals
to measure autofluorescence). At postmortem, samples of
liver, duodenum, and pancreas were harvested and snap-
frozen by immersion in isopentane (2-methylbutane; BDH,
UK) prechilled in liquid nitrogen and stored at −80∘C. For
analysis, the tissue blocks were mounted on OCT medium
(tissue tek II embedding compound; BDH, UK) and 4,
10 𝜇m thick sections cut from each block using a Cryocut E
microtome (Reichert-Jung) and thawed prior to fluorescence
microscopy.
Fluorescence was excited by a 1.8mW helium-neon laser
(532.8 nm) coupled to a liquid light guide with the beam
directed via a band-pass filter at 540 nm into the dichroic
mirror housing for epifluorescence studies (Omega Optical
Inc.). Fluorescence was detected between 630 and 690 nm
using a combination of band-pass (Omega Optical Inc.) and
long-pass (Schott) filters using an Olympus IMT-2 inverted
microscope (10x objective magnification) with epifluores-
cence and phase-contrast attachments.
Fluorescence was quantified using a highly sensitive,
cryogenically cooled CCD (charge-coupled device) camera
(Wright Instruments, Model 1, resolution 400 × 600 pixels)
fitted to the microscope and was processed by an IBM
personal computer into a falsely colour-coded image of the
tissue sections. Fluorescencewas reported in counts per pixel,
corrected for autofluorescence (about 30 counts per pixel).
Tissue samples were taken from two animals per time point
with at least two sections per organ from each animal. Four
readings per tissue section were then taken for a minimum of
16 separate fluorescence readings per time point per organ.
2.2. Photodynamic Therapy. The PDT studies were divided
into 2 sections—the first to optimise the drug light interval
and the second to study the specific effects on the pancreas
and the surrounding organs. In both, the hamsters were
sensitised by an intracaval injection of talaporfin at laparo-
tomy and light from a 664 nm laser (IRIS Medical OcuLight
664) delivered using a 400 𝜇m diameter, cleaved optical fibre
placed perpendicular to and touching the surface of the
targeted organ.There was no shielding of surrounding organs
and light scatter with illumination through and beyond the
directly targeted organswas observed.The laser power output
from the fibre tip was set at 100mW using a power meter
(Model TPM-300, Gentec Electro-Optics Inc., Qc, Canada).
2.3. Drug Light Interval (DLI). Studies to establish the drug
light interval for maximum PDT effect were undertaken on
the liver using a talaporfin dose of 5mg/kg and a light dose
of 50 J, the interval between drug administration and light
delivery being varied from 5 to 240 minutes (2 animals at
each DLI). After light delivery, the laparotomy wound was
closed and the animal was killed 3 days later. At postmortem,
the dimensions of the near spherical zone of PDT necrosis
in the liver were measured in three axes and the volume of
necrosis was calculated: 𝑉 = 4/3𝜋 ⋅ 𝑎 ⋅ 𝑏 ⋅ 𝑐 (where 𝑎, 𝑏, and 𝑐
= perpendicular axes of necrosis in mm). This study showed
that the optimum drug light interval was 15 minutes, so this
value was used in the subsequent safety studies.
2.4. Safety Study. Themain purpose of the studywas to estab-
lish the safety of talaporfin PDT for treatment of pancreatic
cancer, so this part of the work was to examine the effect of
delivering light directly to the pancreas and the immediately
adjacent organs that might be at risk. In addition to the
work in the pancreas, the organs specifically targetedwere the
liver, spleen, duodenum, and retroperitoneum (major blood
vessels), with most studies being undertaken targeting the
pancreas with increasing drug and light doses. The resources
available made it unrealistic to treat each target organ under
all the conditions under consideration, so only selected values
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Table 1: Summary of treatment response of individual hamsters in the safety study.
Target organ Drug dose (mg/kg) Light dose (J) Day of cull Comment
Liver
1 50 3 Macroscopic lesion
1 50 3 Macroscopic lesion, adhesion to colon
1 50 21 Small superficial lesion, adhesion to colon
1 50 21 Small superficial lesion
5 50 3 Large lesion with adhesion to stomach
5 50 3 Large lesion with adjacent duodenal injury
Pancreas
1 20 3 Minimal erythema
1 20 3 No definite effect
5 20 3 No lesion in pancreas. Adhesions and full thickness gastriclesion
1 20 21 No lesions
1 20 21 No lesions
1 25 21 No lesion in pancreas. Adhesion to liver
5 20 21 No lesion in pancreas. Scar in stomach
5 20 21 No lesion in pancreas. Scar in stomach
5 50 12 (>10% weight loss) Lesion in pancreas, multiple adhesions, ascites, smallbowel perforation
5 50 13 (>10% weight loss) Lesion in pancreas, multiple adhesions, small and largebowel perforation
Duodenum 2 15 3 Sealed perforation, adhesions
2 20 3 Sealed perforation, adhesions
Spleen 1 20 3 Small lesion, minor bowel adhesion
1 20 3 Small lesion and subcapsular haematoma
Aorta 2 15 3 No lesions seen
2 15 3 No lesions seen
of the drug and light doses were studied. This approach
was felt to be justified as the value of the whole study was
essentially to compare the safety of talaporfin PDT with that
of PDT in these organs with other photosensitisers, as has
been reported in many earlier publications from this and
other centres. The actual treatment parameters studied are
shown in Table 1.
After treatment and recovery, the hamsters were killed
at 2 different time points. The first group was culled at
72 to 96 hours, known to be the best time interval to
ascertain the maximum extent of PDT tissue injury (Day
3 group). Hamsters in the second group were allowed to
recover for 21 days as a survival study and were then culled
to establish whether the healing of PDT-treated areas was
satisfactory in terms of structural integrity and function of
organs (Day 21 group). Any animal that had lost more than
10% of its pretreatment weight prior to the scheduled day for
culling was killed immediately, in accordance with the care
of laboratory animals guidelines. The effects of PDT were
documented at postmortem. Apart from the liver, the treated
organs were too small for accurate quantification of the
extent of necrosis, so the results were limited to macroscopic
assessment for evidence of necrosis, perforation, leakage of
blood, bile or gastrointestinal contents, gastric or duodenal
ulceration, and ascites.
The pancreas, free edge of lesser omentum, duodenum,
stomach, aorta, vena cava, bile duct, and liverwere removed at
necropsy if macroscopic lesions were evident, or if these were
the targeted tissue sites, regardless of obvious PDT lesions.
Tissuewas preserved in formalin and processed for wax block
sectioning and haematoxylin-eosin staining for histological
analysis. One unsensitised animal was treated with 100 J of
light at 100mW targeted at the pancreas to exclude a thermal
laser effect. Another received 5mg/kg talaporfinwithout light
activation to exclude any dark toxicity.
3. Results
3.1. Fluorescence Microscopy. The results are shown in
Figure 1. The highest drug concentrations were seen in the
liver with the peak at one hour. Intermediate levels were
seen in the duodenum and with the lowest values being
documented in the pancreas. In the pancreas and duodenum,
peak levels were seen after 15 minutes with a second slightly
lower peak at 2 hours, after which the concentration fell in all
3 organs.
3.2. Drug Light Interval (DLI). Full thickness liver lobe
lesions (3–5mm thickness) were seen at all DLI measure-
ments up to 4 hours. The lesions were well demarcated and
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Figure 1: Fluorescence (in counts per pixel ± SD as a log scale,
corrected for autofluorescence) measured in cryosections of liver,
duodenum, and pancreas as a function of the time after adminis-
tration of 5mg/kg talaporfin.
Liver PDT lesion volumes
144
167
84
44.8
26.9
0
20
40
60
80
100
120
140
160
180
200
5 15 30 60 240
Drug light interval (minutes)
Liver PDT lesion volumes
Cu
bi
c (
m
m
) (
+
/
−
SD
)
Figure 2: Volume of PDT necrosis in liver from hamsters treated
with 50 J red light (664 nm) as a function of time after administra-
tion of 5mg/kg talaporfin.
roughly spherical in shape. The volume of necrosis as a
function of the DLI is shown in Figure 2.The greatest volume
of necrosis was observed with a 15 minute DLI (167mm3
(𝑛 = 3; SD 19.7mm3)) and this interval was therefore chosen
for the subsequent safety studies. Lesions at longer intervals
became progressively smaller.
3.3. Safety Study. All animals in the safety study were treated
with a DLI of 15 minutes. The results for individual animals
are summarised in Table 1. No lesionswere seen in the control
animals treated with drug alone or light alone.
3.3.1. General Morbidity. All animals lost some weight ini-
tially, up to 5% of baseline body weight, indicating a degree
of physical harm as a result of the laparotomy and PDT treat-
ment, compared to the control animals having laparotomy
and drug alone or light alone. Recovery, including regaining
lost weight, was universal by 21 days post-PDT in all but the
two hamsters which received high dose pancreatic PDT who
were culled prematurely for severe complications.
3.3.2. Liver. Four animals in the Day 3 group (including 2
from the DLI study) and two in the Day 21 group underwent
PDT of the middle or left liver lobes with a 15-minute DLI.
Those treated with the highest doses of drug (5mg/kg) and
light (50 J) showed macroscopic PDT lesions with adhesions
to adjacent stomach, small bowel, or colon. A section of
treated liver is shown in Figure 3(a). Those treated under
less severe conditions, including the two hamsters in the Day
21 group, showed similar, but milder effects. There were no
fatal complications and no evidence of biliary obstruction or
gallbladder injury.
3.3.3. Pancreas. Ten animals underwent PDT with light
applied directly to the pancreas and aDLI of 15minutes.Three
were culled on day 3 and 7 on day 21. With a light dose of 20–
25 J, no pancreatic lesions were seen with a drug dose up to
the maximum of 5mg/kg. However, some of these animals
showed lesions in adjacent organs. Full thickness gastric
lesions, but without evidence of perforation, were seen in one
animal culled on day 3 and in 2 culled on day 21 (all treated
with 5mg/kg, 20 J). Adhesions were noted in 1 of 3 animals
culled on day 3 post-PDT and in 1 of 5 animals in the group
culled on day 21.There was no evidence of biliary obstruction
at light doses of up to 25 J. Significant pancreatic lesions were
seen in 2 animals treatedwith 50 J and 5mg/kg.These animals
were culled at 12 and 13 days due tomore than 10%weight loss.
At necropsy there was macroscopic evidence of duodenal
perforation, full thickness gastric lesions, and peritonitis with
extensive local adhesions to liver, stomach, small bowel, and
colon in both. A histological section showing the junction of
normal and PDT-treated pancreas is shown in Figure 3(b).
3.3.4. Duodenum. The most severe damage was seen with
duodenal treatment. Two animals treated with the low doses
of 2mg/kg and 15–20 J showed full thickness lesions with
sealed perforations and adhesions to adjacent liver and colon.
3.3.5. Spleen. Two animals in the Day 3 group had splenic
PDT at 1mg/kg and 20 J. There was localised puckering and
scarring at the site of PDT and one animal had histological
evidence of a subcapsular haematoma, but with no evidence
of clinical distress.
3.3.6. Aorta and IVC. No definite PDT lesions were found
macroscopically or on histology in two animals treated with
PDT at 2mg/kg and 15 J, when the laser fibre was used to
directly target the exposed vessels.
The severity of scarring and adhesions increased with the
severity of the treatment conditions (drug and light doses),
as expected. Moderate adhesions were observed between
PDT-treated liver and bowel, and PDT-treated pancreas and
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Figure 3: (a)Histological section of liver 3 days after treatmentwith PDT showing the sharp demarcation betweenPDTnecrosis anduntreated
liver with a few islands of viable tissue in the necrotic area. (b) Histological section of pancreas 12 days after treatment demonstrating the
junction of normal pancreas (top left) with PDT necrosis (bottom right).
bowel. In the maximally treated animals, adhesions were
more extensive and were seen in multiple areas between the
pancreas, liver, and intestinal tract.
4. Discussion
Destroying a cancer of localised and known extent with PDT
is relatively straightforward. A key issue is what happens
where the cancer meets normal tissue and how the treated
area heals. The aim of this study was to establish if talaporfin
PDT is safe for the treatment of pancreatic adenocarcinoma.
Previous hamster studies have looked at the effect of PDT
with mTHPC, with which the optimum drug light interval
is up to 4 days for treating cancers of the pancreas [19]. In
this work, treating normal pancreas was shown to be safe, but
the duodenum was found to be vulnerable under conditions
required for cancer therapy [22]. These hamster results were
borne out in our clinical study withmTHPC [17].The present
study shows that the most effective DLI for talaporfin is 15
minutes, at which time the drug is predominantly in the
vasculature, so different effects might be anticipated. It is of
interest to note that the highest concentration of drug in the
liver measured by fluorescence was at one hour, whereas the
volume of necrosis was nearly 4 times greater at 15 minutes
than it was at one hour, suggesting that the drug is more
effective if it remains in the vasculature. Nevertheless, our
results show that PDT with talaporfin is remarkably similar
to that seen with mTHPC. In the liver, quite large areas of
necrosis can be produced, but these heal safely and without
sequelae.
One of the major attractions of PDT is that there is no
significant change in tissue temperature during treatment, so
connective tissues like collagen are largely unaffected [25].
This helps to maintain the mechanical integrity of tissue,
particularly hollow organs. However, if the conditions used
for treating a cancer cause serious damage to the normal
tissue in which the cancer arose or adjacent normal tissues,
then the treatment may be detrimental. For this reason, it is
essential to understand what PDT does to a normal organ
before using it to treat a cancer in that organ. In the case of
the pancreas, the risks are that PDT might cause a fistula or
lead to duct obstruction with consequent pancreatitis and
also that it might seriously injure adjacent tissues like the
duodenum.The pancreas, however, seems relatively resistant
and lesions can only be produced with high drug (5mg/kg)
and light (50 J) doses. These lesions heal safely, but light
scattered from the pancreas under these conditions causes
overwhelming damage to adjacent organs. Perforations to
the large and small intestine were seen, together with full
thickness lesions in the stomach wall, ascites, and multiple
adhesions. Preservation of collagen in the gastric wall proba-
bly explained why the stomach was less prone to perforation
than the thinner-walled duodenumbut, fortunately, therewas
no evidence of biliary tree or vascular injury.
These results help to define how PDT with talaporfin
might safely be used for cancers of the pancreas in humans.
The red light used in this study (664 nm) produced effects up
to 6–8mmdeep in tissue. Due to the smaller scale of the ham-
ster pancreas, it is not unexpected that a significant amount
of light directed at the head of the pancreas was scattered to
the duodenum. However, in humans, the distances are much
greater, so that as long as the light delivery fibre is separated
from the duodenum bymore than about 1 cm (for example by
positioning the fibre tip 1 cm deep into the pancreatic tissue),
duodenal damage is unlikely, as shown in the clinical studies
with mTHPC.
Previous work has also looked at the effect of PDT with
mTHPC on cancers of pancreatic origin transplanted into the
hamster pancreas [19]. The present study did not extend to
looking at the effects on transplanted cancers, as our aim was
to establish safety. Skin photosensitivity was also not assessed
in the present study, but other publications have shown that
this is a maximum of 1-2 weeks for talaporfin [18].
In patients, talaporfin doses of 2mg/kg or 40mg/m2 have
been used safely in Phase I and II studies of solid tumours
[18, 21]. The light dose delivered determines the size of the
PDT lesion, so that larger tumourmasses can be treated using
multiple laser fibres or with sequential fibre placement within
a treatment window of 15 minutes to 1 hour after injection
of photosensitiser. Waiting for longer periods of up to
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4 hours, as shown in Figure 2, to allow talaporfin to distribute
into the extracellular matrix, did not seem advantageous
in this study, as fluorescence data showed no increase in
talaporfin tissue levels than earlier time periods and PDT
lesions seen in the liver were smaller than at 15minutes.These
results are comparable to those reported for another short
acting photosensitiser, verteporfin, in both experimental and
clinical studies [26, 27].
It is concluded that the results of the current work,
together with other published experimental and clinical data,
support the use of talaporfin in Phase 1 studies of PDT for
pancreatic cancer in inoperable patients with localised dis-
ease, although care must be taken to minimise the exposure
of the duodenum to light.
Abbreviations
mTHPC: Meso-tetrahydroxyphenyl chlorin
PDT: Photodynamic therapy
DLI: Drug light interval.
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